91,331 Shares in Kenvue Inc. $KVUE Bought by Camelot Portfolios LLC

Key Points

• Camelot Portfolios LLC bought 91,331 shares of Kenvue (NYSE:KVUE) in Q4, about $1.575 million, representing 1.0% of its portfolio and the stock's 20th largest position.
• Sell-side analysts hold a consensus "Hold" rating on KVUE with an average target price of $19.33 (three Buys, thirteen Holds) after several recent price-target cuts and a downgrade from Jefferies.
• Kenvue beat Q4 estimates with $0.27 EPS (vs. $0.22) and $3.78B revenue (+3.2% YoY), and pays a roughly 4.7% dividend (annualized $0.83) though the payout ratio is about 107.8%.

Camelot Portfolios LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 91,331 shares of the company's stock, valued at approximately $1,575,000. Kenvue comprises 1.0% of Camelot Portfolios LLC's portfolio, making the stock its 20th biggest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Physician Wealth Advisors Inc. boosted its position in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after acquiring an additional 618 shares during the last quarter. Cornerstone Planning Group LLC boosted its position in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company's stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. NBT Bank N A NY boosted its position in shares of Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company's stock worth $25,000 after acquiring an additional 1,006 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of Kenvue during the third quarter worth $25,000. Finally, Golden State Wealth Management LLC boosted its position in shares of Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company's stock worth $32,000 after acquiring an additional 1,190 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on KVUE shares. Argus upgraded shares of Kenvue to a "hold" rating in a research report on Friday, March 6th. Citigroup decreased their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 15th. Canaccord Genuity Group upped their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a research note on Wednesday, February 18th. UBS Group decreased their price target on shares of Kenvue from $19.00 to $18.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group downgraded shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $19.33.

Kenvue Price Performance

Kenvue stock opened at $17.49 on Monday. The company has a market cap of $33.57 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 3.97 and a beta of 0.61. The firm's fifty day moving average is $17.82 and its 200 day moving average is $17.16. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. Kenvue's revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 earnings per share. Sell-side analysts forecast that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. Kenvue's dividend payout ratio is currently 107.79%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.